TransMedics, Inc.

2014/10/27 15:36


AsiaNet 58367(1176)


  Photo - http://photos.prnewswire.com/prnh/20141024/154161













▽TransMedics, Inc.について
TransMedics Inc.は移植用ドナー器官のポータブル生体外機械潅流、評価の世界リーダーである。米マサチューセッツ州アンドーバーに本社を置く同社はより多くのよりよい移植用器官に対する満たされていない必要に対応するために創立された。詳しい情報はwww.TransMedics.comへ。


Neal Beswick
TransMedics, Inc.


The TransMedics(R) Organ Care System (OCS(TM)) Heart Technology Was Used to Perform The World's First Series of Adult Human Heart Transplants From Donors After Circulatory Death (DCD Donors) at St Vincent's Hospital in Sydney, Australia

ANDOVER, Mass., Oct. 24, 2014 /PRN=KYODO JBN/ --

    TransMedics announces that its OCS(TM) Heart technology was used to
preserve and assess the world's first series of three successful adult heart
transplant procedures from hearts donated from donors after circulatory death
(DCD) by the St. Vincent's Hospital Heart Transplant team. All patients who
received these groundbreaking transplants have recovered very well. This
achievement represents a pivotal new milestone in heart transplantation
worldwide, and it was carried out following pioneering basic and translational
research undertaken by the Victor Chang Cardiac Research Institute and St
Vincent's Hospital using the OCSTM Heart technology.

    Photo - http://photos.prnewswire.com/prnh/20141024/154161

    These hearts were retrieved from donors whose hearts had stopped beating.
Currently, these DCD donors are not considered for heart transplantation due to
the limitations of cold storage preservation technique. These hearts were
retrieved, resuscitated to a normal beating state and clinically assessed using
the TransMedics OCS(TM) Heart technology. The OCS(TM) technology platform is
the only medical device capable of maintaining donor organs in near physiologic
and functioning state outside of the human body from the time the organ is
removed from the donor until it is ready to be transplanted into a suitable

    "The OCS(TM) Heart system was paramount to the success of this clinical
milestone in heart transplantation as it enabled us to fully assess the donor
heart function and metabolic state before transplantation," said Dr. Kumud
Dhital, Prof. of Cardiothoracic Surgery at St. Vincent's Hospital and the lead
surgeon who performed the DCD heart transplants.

    "The ability to safely transplant a donor heart from DCD donors could be a
paradigm shift to potentially increase the pool of viable donor hearts to help
more patients suffering from end-stage heart failure," said Dr. Waleed
Hassanein, President and CEO of TransMedics, Inc. "We are actively engaged in
four large pivotal trials for hearts, lungs and livers in the U.S. to bring the
revolutionary OCS(TM) technology to the U.S. market hopefully starting in
2015," said Dr. Hassanein.

    What is the TransMedics Organ Care System (OCS(TM))?

    Since the advent of organ transplantation, the cornerstone of organ
preservation has been cold ischemic storage (placing organs on ice). Although
this method is intended to reduce the extent of organ damage during transport,
significant deterioration of the donated organ still occurs. The longer the
organ is kept on ice, the greater the damage. Moreover, the cold storage
technique does not enable any resuscitative or assessment while the organ is
being transported from donor to recipient. Given the limitations of cold
storage, it is estimated that globally 60-65% of donor hearts cannot ultimately
be used for transplantation.

    TransMedics has developed the world's only portable medical device capable
of overcoming the limitations of cold storage for organ transplantation. The
OCS(TM) technology was designed to provide a comprehensive solution to all
three key limitations of the cold storage technique, as it:

    -- Minimizes cold ischemia injury by perfusing the heart with warm
       oxygenated blood;

    -- Optimizes the condition of the organ by replenishing oxygen, nutrients,
       and hormones that would otherwise become depleted;

    -- Provides continuous monitoring and assessment of the organ until the
       point of transplantation

    These unique capabilities of the OCS technology have the potential to:

    -- Increase utilization of current donor organs

    -- Improve patient survival

    -- Reduce post-transplant complications

    -- Improve cost-effectiveness of the transplant procedure

    About TransMedics, Inc.

    TransMedics Inc. is the world's leader in portable ex-vivo machine
perfusion and assessment of donor organs for transplantation. Headquartered in
Andover, Massachusetts, the company was founded to address the unmet need for
more and better organs for transplantation. For more information, please visit

    SOURCE: TransMedics, Inc.

    CONTACT: Neal Beswick, TransMedics, Inc., nbeswick@transmedics.com, Tel: